Table 1 Mean (SD) spectral quality per group. Only data points with an SNR > 10, FWHM < 0.1, and a CRLB < 20% were included in the final analysis.
Parameter | Psilocybin | Placebo | t value | P value |
|---|---|---|---|---|
Medial prefrontal cortex | ||||
Relative Cramer–Rao lower bound (%); n | ||||
Glutamate | 2.62 (0.57); 24 | 2.71 (0.60); 28 | −0.54 | 0.58 |
GABA | 13.33 (3.52); 15 | 14.65 (3.33); 17 | −1.08 | 0.29 |
NAA + NAAG | 2.37 (0.49); 24 | 2.32 (0.55); 28 | 0.36 | 0.71 |
Myoinositol | 4.33 (2.14); 24 | 4.11 (1.42); 28 | 0.45 | 0.65 |
Signal to noise ratio | 36.87 (4.77) | 37.96 (6.52) | −0.67 | 0.50 |
Full-width at half-maximum peak height | 0.04 (0.01) | 0.04 (0.01) | −0.307 | 0.76 |
Hippocampus | ||||
Relative Cramer–Rao lower bound (%); n | ||||
Glutamate | 5.85 (2.32); 21 | 5.00 (1.73); 25 | 1.43 | 0.16 |
GABA | 16.60 (1.67); 5 | 14.50 (3.07); 8 | 1.39 | 0.19 |
NAA + NAAG | 2.90 (0.77); 21 | 2.96 (0.93); 25 | −0.22 | 0.83 |
Myoinositol | 4.70 (1.26); 20 | 4.62 (3.12); 24 | 0.10 | 0.92 |
Signal to noise ratio | 20.57 (5.61) | 21.16 (6.86) | −0.31 | 0.75 |
Full-width at half-maximum peak height | 0.07 (0.01) | 0.06 (0.01) | 1.80 | 0.08 |
